Product Information
DIFICID 200 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $248.3785 per EA under NDC 52015008001. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 27, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
52015008001
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FIDAXOMICINApproval Type
New Drug (NDA)
FDA Application
NDA201699FDA Approved
5/27/2011
TE Code
AB
On Market Since
5/27/2011
Pharmacological Classes
Price Statistics
The NADAC for DIFICID 200 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 72.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $248.3785 per EA |
|---|---|
| All-time high | $249.5128 (May 14, 2025) |
| All-time low | $142.8742 (Dec 18, 2013) |
| 52-week high | $249.0671 |
| 52-week low | $248.3785 |
| Median price | $194.2238 |
| Average price | $197.4163 |
| Largest weekly change | +6.0% (Jan 17, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 64% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fidaxomicin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DIFICID 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DIFICID 200 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $248.3785 per EA (NDC 52015008001), effective Sep 30, 2026.
How has the price of DIFICID 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for DIFICID 200 MG TABLET has risen 72.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DIFICID 200 MG TABLET?
Since Nov 28, 2013, the NADAC for DIFICID 200 MG TABLET has ranged from a low of $142.8742 (Dec 18, 2013) to a high of $249.5128 (May 14, 2025), with a median of $194.2238 per EA.
Are there cheaper alternatives to DIFICID 200 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FIDAXOMICIN 200 MG TABLET, is $90.5046 per EA — about 64% below DIFICID 200 MG TABLET.
Who manufactures DIFICID 200 MG TABLET?
DIFICID 200 MG TABLET (NDC 52015008001) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.